Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05275478 · ClinicalTrials.gov registry record · Phase 1

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

A Phase 1 study of Locally Advanced Solid Tumor, sponsored by Tango Therapeutics.

Active
Registry status
Phase 1
Development phase
192
Enrollment target
20
Study locations

NCT05275478 is a Phase 1 study of Locally Advanced Solid Tumor that is active but no longer recruiting, run by Tango Therapeutics. The registered enrollment target is 192 participants, below the 226-participant average among 13 other Locally Advanced Solid Tumor trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05275478, a Phase 1 study of Locally Advanced Solid Tumor, is active but no longer recruiting, sponsored by Tango Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
192 participants
Enrollment target
20
Study locations

Study Summary

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG908, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 192 participants.

Conditions Studied

Locally Advanced Solid Tumor

Interventions

  • DRUG TNG908

Study Locations (20)

Other

  • Institut Bergonié - Bordeaux
  • Centre Léon Bérard - Lyon
  • EDOG Institut de Cancerologie de l'Ouest - Saint-Herblain
  • Institut Oncopole Claudius Regaud - Toulouse
  • Institute Gustav Roussy - Villejuif

California

  • University of California Los Angeles - Los Angeles
  • University of California San Francisco - San Francisco

Colorado

  • Sarah Cannon Research Institute at HealthONE - Denver
  • Grand Valley Oncology - Grand Junction

Illinois

  • Northwestern University - Chicago
  • Carle Cancer Center - Urbana

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana Farber Cancer Institute - Boston

New York

  • NYU Langone Health - New York
  • Memorial Sloan Kettering Cancer Center - New York

Florida

  • Florida Cancer Specialists & Research Institute - Lake Mary

Missouri

  • Washington University - St Louis

Trial Details

FieldValue
Enrollment Target 192 participants
Start Date 2022-03-23
Est. Completion 2025-12
Phase Phase 1

Sponsor

Tango Therapeutics

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05275478

The ClinicalTrials.gov registry entry for NCT05275478 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 226-participant average among 13 other Locally Advanced Solid Tumor trials with a reported enrollment target (15% lower). The listed sponsor is Tango Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Locally Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which TNG908 is the first listed.

NCT05275478 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT05275478 about?

NCT05275478 is a clinical study titled "Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors". This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG908, is a sel...

What is the current status of trial NCT05275478?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 192 participants. The study started on 2022-03-23. Estimated completion is 2025-12.

What conditions does trial NCT05275478 study?

This clinical trial studies the following conditions: Locally Advanced Solid Tumor.

What interventions are being tested in trial NCT05275478?

The interventions under investigation include: TNG908 (DRUG).

Who is sponsoring clinical trial NCT05275478?

This trial is sponsored by Tango Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05275478 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Locally Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Locally Advanced Solid Tumor

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.